1YBottom 25% of the group
Rank 138 of 149 funds
Return −10.91%
1Y returns of 149 funds in the US Equity group, sorted from highest to lowest. This fund ranks 138No. 1 is K-US500X-C(A) +25.92%
Asset Plus U.S. Small Cap Focus Fund
Shows where this fund stands in its group. Not investment advice · Data as of 4 Nov 2026
ASP-USSMALL-A invests through the master fund Driehaus US Small Cap Equity Fund 101.92%
This fundASP-USSMALL-A
The fund that actually investsDriehaus US Small Cap Equity FundThis fund and the master fund each charge their own fees. See the fees section of this page for the actual fees
Guardant Health GH2.34%
Praxis Precision PRAX2.04%Data as of 30 Sep 2026 · Top 6 shown, the rest grouped as Other · per Driehaus fact sheet · Country inferred from the name of a single-country fund
Over the past year it was in the bottom 25% of its group; there is no rank for a longer period yet
No. 1 is K-US500X-C(A) +25.92%
Each bar is one fund in the AIMC US Equity group, sorted from highest to lowest return · Every share class is counted, and only funds with a full track record for the period are included · Calculated from NAV as of 4 Nov 2026
Past performance is not a guarantee of future results
| YTD | 1W | 2W | 1M | 3M | 6M | 1Y | MAX |
|---|---|---|---|---|---|---|---|
| −9.95% | −2.09% | +0.31% | −5.85% | −10.01% | −12.05% | −10.91% | −15.58% |
Total return over each period, matching the NAV chart periods · Not annualised
| Year | Jan | Feb | Mar | Apr | May | Jun |
|---|
Largest drawdown in the selected period −32.90% Previous peak 25 Nov 2024 (NAV 12.2624) → Trough 30 Mar 2026 (NAV 8.2279) · Not back to the previous peak as of 3 Nov 2026
Currently −31.16% from the peak NAV of 12.2624 (25 Nov 2024)
Over 1 year, ASP-USSMALL-A returned -0.47 per unit of volatility, ranking 79 of 84 funds · The highest is KKP EWUS500-UH (1.82)
กองทุนมีนโยบายเน้นลงทุนในกองทุน Driehaus US Small Cap Equity Fund (กองทุนหลัก) Class S USD Acc โดยกองทุนจะลงทุนในกองทุนหลักด้วยสกุลเงินดอลลาร์สหรัฐ (USD) และกองทุนหลักจะนำเงินไปลงทุนต่อในสกุลเงินดอลลาร์สหรัฐ (USD) เป็นสกุลเงินหลัก ซึ่งกองทุนหลักมี Carne Global Fund Managers (Ireland) Limited… Its largest holdings are HEPSMCS ID 101.92% (fact sheet 30 Sep 2026)
Risk level 6 of 8 (High risk). Since 29 Nov 2023, its NAV has fallen as much as −32.90% from its peak.
Actual total expense ratio (TER) 2.48% a year, against a ceiling of 3.85%. Management fee 1.61%. Front-end fee 1.50%. Back-end fee 0.00%. (Fact sheet 31 Aug 2026)
No. Gains or losses accumulate in the NAV, and investors receive their return when they redeem units
Minimum first purchase 1,000 THB, subsequent purchases 1,000 THB. Buy orders accepted until 15:30, sell orders until 15:30, and redemption proceeds are paid T+4
Almost fully hedged. As of 30 Sep 2026, 100.79% of the value of its foreign investments was hedged
They are share classes of the same fund and invest in the same assets. They differ only in each class's terms, such as dividend policy, fees or who can buy · ASP-USSMALL-A: no dividends, TER 2.48% · ASP-USSMALL-SSF: no dividends, TER 2.37%
Past performance is not a guarantee of future results · Investing involves risk. Investors should understand the product's features, return conditions and risks before making an investment decision · This fund invests abroad, so investors may lose or gain from exchange rate movements
Spyre Therapeutics SYRE1.94%
JFrog FROG1.73%
Definium Therapeutics DFTX1.63%
Twist Bioscience TWST1.63%
Xenon Pharmaceuticals XENE1.53%
Zeta Global ZETA1.53%
Edgewise Therapeutics EWTX1.53%
Xometry XMTR1.43%Hospitals, medicines and medical equipment
Praxis Precision PRAXBiotech company that develops drugs for neurological conditions such as epilepsy and tremor
Spyre Therapeutics SYREHospitals, medicines and medical equipment
JFrog FROGIsraeli company whose software helps developers store, secure and release new versions of their apps
Hospitals, medicines and medical equipment
Twist Bioscience TWSTMakes synthetic DNA on silicon chips for drug and genetics research
Hospitals, medicines and medical equipment
Zeta Global ZETAUS company running an AI marketing platform that uses customer data to target emails and ads
Hospitals, medicines and medical equipment
Xometry XMTRUS company running an online platform where businesses order custom parts, matched with thousands of factories
Based on the master fund's share of this fund's value (101.92% as of 30 Sep 2026) × each stock's weight in the master fund · stocks as of 30 Sep 2026 · fact sheet from Driehaus · Illustrations are for explanation only, not individual stock recommendations
| Jul |
|---|
| Aug |
|---|
| Sep |
|---|
| Oct |
|---|
| Nov |
|---|
| Dec |
|---|
| Full year |
|---|
| 2026 | +0.3 | −2.9 | −6.2 | +12.0 | +4.9 | +4.6 | −10.8 | +0.1 | −6.0 | −3.2 | −1.3 | · | −9.9* |
| 2025 | +0.1 | −3.6 | −5.3 | −5.6 | +4.9 | −0.1 | −0.6 | +3.2 | −6.4 | −1.3 | −3.7 | +2.2 | −15.7 |
| 2024 | −2.2 | +3.2 | +2.7 | −10.5 | +4.1 | +1.8 | +9.0 | −2.7 | +1.2 | −0.1 | +10.5 | −8.9 | +6.2 |
| 2023 | · | · | · | · | · | · | · | · | · | · | −0.0 | +4.7 | +4.7* |